Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CANbridge NDA for Rare Disease Therapy Accepted in Taiwan

publication date: Mar 29, 2022

CANbridge Pharma’s NDA for maralixibat oral solution was accepted by Taiwan’s FDA as a therapy for cholestatic pruritus in patients with Alagille syndrome, an orphan disease. One year ago, the company acquired Greater China rights to the drug from Mirum Pharma of California in a $120 million deal. CANbridge has rights to commercialize the drug for three orphan indications: Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia. It filed an NDA for review in China previously, and Mirum is approved to launch the drug in the US. More details....

Stock Symbols: (HK: 1228) (NSDQ: MIRM)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital